orthopedic adverse events among aya patients with all treated with asparaginase
Published 1 year ago • 78 plays • Length 2:49Download video MP4
Download video MP3
Similar videos
-
0:56
long-term overall survival of aya patients with all who complete therapy on dfci consortium trials
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:09
an overview of the management of patients with r/r waldenström’s macroglobulinemia
-
2:41
an overview of the latest advances in hematology
-
2:10
safety & efficacy of nelarabine, pegylated asparaginase and venetoclax in frontline therapy of t-all
-
3:33
the growing role of machine learning in hematological oncology
-
7:25
ai in hematology: advances, challenges, and future applications
-
3:39
applications of ai in hemonc: improving diagnosis & predicting outcomes and response to therapy
-
1:21
the prognostic impact of secondary-type mutations in patients with favorable risk aml
-
8:05
using ai to segment and classify bone marrow cells in patients with aml
-
0:48
an overview of challenges that remain in the treatment of patients with al amyloidosis
-
5:14
current status & updates in the management of al amyloidosis
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:33
main goals for treating patients with al amyloidosis: achieving complete hematologic response
-
2:06
thromboembolic event rates in patients with pv: a real-world analysis
-
2:02
phase ii animate trial investigating pet response-adapted treatment using nivolumab in r/r chl
-
4:38
phase i study of neihulizumab in patients with sr-agvhd or tr-agvhd
-
1:14
the value of enrolling patients with amyloidosis in clinical trials